Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Par Pharmaceutical Companies Inc-Deals & Alliances Report
|
Mar 2011 |
£380 |
100% |
|
Par Pharmaceutical Companies Inc-Therapeutic Competitors
|
Mar 2011 |
£220 |
99% |
|
Par Pharmaceutical Companies Inc-Detailed Product Pipeline
|
Mar 2011 |
£475 |
99% |
NovaDel Pharma, Inc. – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
85% |
|
Rimonabant: The first of the Cannabinoid blockbusters
|
Jun 2007 |
£1,499 |
84% |
Marina Biotech, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
83% |
Optimer Pharmaceuticals Inc
Premium Company Profile
|
Apr 2008 |
£315 |
79% |
|
Analgesics - Singapore
|
Mar 2011 |
£600 |
78% |
|
Pharmaceuticals
|
Sep 2008 |
£1,235 |
78% |
Cachexia Global Clinical Trials Review
Q2, 2011
|
Jun 2011 |
£630 |
77% |
Spectrum Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
76% |
Endometrial Cancer Global Clinical Trials Review
H2, 2011
|
Dec 2011 |
£630 |
75% |
|
Nanomedicine
|
Jul 2009 |
£2,500 |
75% |
Top 50 Pharmaceutical Companies Report - Global
Business Performance Analysis
|
Aug 2011 |
£820 |
74% |
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
73% |
Pulmonary Fibrosis Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
73% |
Generic Pharmaceuticals Industry Report - Global
Business Performance Analysis
|
Aug 2011 |
£950 |
72% |
|
Anti-Hypertensive Drugs
|
Feb 2010 |
£2,500 |
71% |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
Sep 2006 |
£1,450 |
69% |
Generic Drugs
The Global Market
|
Sep 2011 |
£3,065 |
68% |
|
Anti-Migraine Drugs
|
Feb 2010 |
£2,500 |
68% |
World Market for Prescription Generic Drugs
6th Edition
|
Apr 2008 |
£2,525 |
67% |
|
Intranasal Drug Delivery
|
Jan 2011 |
£2,845 |
67% |
Inflammatory Bowel Disease - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
67% |
|
Generic Drugs: The Global Market--Focus on Asia
|
Sep 2011 |
£2,465 |
67% |
|
Generic Drugs: The Global Market--Focus on Europe
|
Sep 2011 |
£2,465 |
66% |
BioAlliance Pharma SA – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
66% |
|
Cardiovascular Drugs
|
Apr 2010 |
£2,815 |
66% |
|
Generic Drugs: The Global Market--Focus on the Americas
|
Sep 2011 |
£2,465 |
66% |
|
Testosterone Replacement Therapy (TRT)
|
Apr 2011 |
£2,910 |
66% |
